Biotechnology

A new partnership with AI firm Basepath Health will help Children's Mercy treat five times more children with complex and rare genetic diseases.

New FolinicActive™ offers a multi-pathway folate for the 15-25% of adults who report adverse effects from standard L-methylfolate supplements.

A new bispecific antibody, TRIV-573, enters clinical trials, targeting both skin barrier and inflammation to redefine atopic dermatitis therapy.

With 12% weight loss in a pivotal trial, Vincentage Pharma's VCT220 pill is set to challenge injectables and reshape China's obesity drug market.

The life sciences news hub earned prestigious Neal and Azbee National Gold awards, highlighting the growing influence of expert-driven B2B journalism.

The biotech firm raises cash via a complex warrant deal, diluting shares to fund its promising but challenging RNAi therapy for deadly KRAS-driven cancers.

New data reveals TARA-002 has a 55% complete response rate at one year for NMIBC, offering a promising, safer alternative to standard care.

A new oral drug for depression shows rapid, robust effects in a key trial, offering hope for millions by targeting a different brain pathway.

Pharma veteran Shyamakant Giri takes the helm at Apothecon Group, signaling an aggressive push into global regulated markets backed by Everstone Capital.

Glucotrack seeks FDA trial approval for its revolutionary 3-year implantable glucose monitor, racing against financial clocks to change diabetes care.

As its CFO presents at a top NYC conference, Healios K.K. advances novel stem cell treatments for ARDS, stroke, and cancer into critical global trials.

Edesa Biotech pushes its pipeline forward with a new vitiligo trial and promising ARDS data, but rising R&D costs highlight the high stakes of innovation.

The biotech firm is set to launch its first commercial products, using an innovative strategy to tackle long-neglected markets in women's healthcare.

A key workshop aims to bridge the gap between FDA policy and patient needs, seeking to streamline therapy development for millions with rare diseases.

The Nexus Forum launches to connect China's booming biotech scene with global pharma, capitalizing on a major shift in worldwide drug discovery and deal-making.

NFL legend Brett Favre reports gains from an experimental Parkinson's drug, but what does the science say about this potential breakthrough treatment?

Senti Biosciences advances its AML cell therapy to a registrational trial after FDA meeting and a key discovery that quadruples patient response rates.

Rubicon Point Partners and Canyon Partners Real Estate acquired a Santa Clara R&D campus, signaling a major bet on Silicon Valley's real estate backed by accelerating demand for specialized flex space.

The biopharma posts record Q1 revenue and profit, driven by its flagship DefenCath and a key acquisition, while a promising pipeline signals future growth.

OrganOx names Terumo's Naoya Iwata as new CEO, signaling a major push to expand its life-saving organ transplant technology across the globe.